Drug-Eluting Balloon Market Size & Share | Report 2022, 2027

Drug-Eluting Balloon Market to 2027 - Global Analysis and Forecasts by Product Type (Coronary Drug-Eluting Balloons, Peripheral Drug Eluting Balloons, and Other Product Types); End User (Hospitals, Cath Labs & Cardiac Centers, and Ambulatory Surgical Centers), and Geography

  • Report Code : TIPRE00003085
  • Category : Medical Device
  • Status : Published
  • No. of Pages : 149
Buy Now

The Drug-Eluting Balloon market was valued at US$ 516.65 million in 2018, it is expected to grow at a CAGR of 15.6% from 2019 to 2027, says The Insight Partners

Drug-eluting balloons are defined as the semi-compliant conventional angioplasty balloons that are covered with anti-proliferative drugs that are released in the walls of blood vessels during balloon inflation, majorly at nominal pressures. These balloons help to attenuate cellularity significantly and eliminates the need for repetitive vascularization. The growth of the Drug-Eluting Balloon market is attributed to the rising vascular disease incidences, growing product innovations and rising geriatric population. Whereas, the market is expected to have slow growth due to the high cost of procedures and products and stringent regulations for approval during the forecast period.

The Drug-Eluting Balloon market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.

Lucrative Regions for Drug-Eluting Balloon Market



Lucrative Regions for Drug-Eluting Balloon in Healthcare Market
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Market Insights

Growing Applications of Drug-Eluting Balloon in Healthcare to Drive Drug-Eluting Balloon Market Growth

Drug-eluting balloons are an emerging technology that has enabled to treat various chronic conditions, such as cardiovascular conditions and peripheral vascular diseases. Innovations in medical interventions, through advanced products and technologies, have eased the treatment of blood vessel blockages. The rising incidences of cardiovascular, peripheral vascular, and neurovascular diseases, among others, is a major factor driving the drug-eluting balloons market.

For instance, cardiovascular diseases are growing drastically across the world. The various factors such as obesity, less physical activities, increased stress, and a shift in the lifestyle and resulted in the growing incidences of cardiovascular disease. 

Factors such as growing obesity incidence, diminished physical activities, increased stress, and shifting lifestyle have resulted in the rise in incidences of cardiovascular diseases. According to a report by the American College of Cardiology February 2019, cardiovascular diseases are the primary cause of death in the US. In 2016, the US registered 635,260 deaths caused by cardiovascular conditions. In addition, the report also mentions the decrease of 31.8% in deaths caused by coronary heart diseases from 2006 to 2016. Thus, the use of drug-eluting balloons has helped to treat people with cardiovascular conditions. Similarly, according to the statistics published by the WHO in May 2017, cardiovascular conditions are the cause of numerous deaths in the world, and there is a significant rise in the incidences of vascular diseases worldwide. As per the Centers for Disease Control and Prevention, every year, ~1–2 persons per 1,000 people are affected by deep vein thrombosis (DVT) in the US. Such escalating incidences of vascular diseases are likely to further increase the demand for drug-eluting balloons in the coming years.

The drug-eluting balloon market comprises various market leaders and emerging players. Medtronic plc, Boston Scientific Corporation, Cook Medical, and Royal Philips (a part of Koninklijke Philips N.V) are among the market leaders, while there are various the emerging players operating in the market. These companies are engaged in the constant development of various medical devices. They have developed these products further to ensure their sustenance in the global market. For instance, in November 2019, Medtronic received the US Food and Drug Administration (FDA) approval for its In.Pact AV drug-coated balloons that are used in the treatment of failing arteriovenous (AV) access in patients suffering from endstage renal disease (ESRD), undergoing dialysis. Similarly, Royal Philips has launched two new balloons to its Stellarex portfolio of 0.035-inch, low-dose, drug-coated balloons; the additions include 200mm and 150mm Stellarex 0.035-inch low-dose drug-coated balloons. The products have received FDA approval for the treatment of de novo and restenotic lesions in native superficial femoral or popliteal arteries in upper legs.

Such launches of innovative products by market leaders and new players are driving the growth of the drug-eluting balloon market. This is mainly attributed to the fact that these products have expanded treatment options for physicians to treat peripheral artery diseases (PADs), cardiovascular conditions, and renal artery conditions, and so on. The incidence of heart diseases is high among geriatric population. Particularly, the older people with weak immunity and major other health problems are more prone to heart diseases. For instance, the number of Americans with age 65 and above is anticipated to rise from US$ 46 million in 2016 to above US$ 98 million by 2060. Moreover, the share of this group is likely to reach grow ~24% from 15% of the world population during the aforementioned timeline.

In 2017, Europe had the world’s largest percentage of population with age 60 or above (25%). This trend of aging is approaching the other parts of the world as well; all regions of the world, except Africa, would have nearly a quarter or more of their populations with age 60 and above. The number of elderly people in the world is anticipated to reach US$ 1.4 billion by 2030 and US$ 2.1 billion by 2050, while it would further rise to more than US$ 3.1 billion by 2100.

The elderly population is more prompt to have a typical presentation, comorbid conditions, and unfavorable outcomes. The major reasons for heart diseases are related to the age-related structural and functional changes in the cardiovascular system. Thus, the increasing coronary disease incidences with rising geriatric population in the world would lead to a greater demand for drug-eluting balloons for their treatment.

Product Type-Based Insights

In terms of product type, the Drug-Eluting Balloon market is segmented into coronary drug eluting balloons, peripheral drug eluting balloons, others. The peripheral drug eluting balloons segment held the largest share of the market in 2018. However, the coronary drug eluting balloons segment is anticipated to register the highest CAGR of 17.6% in the market during the Forecast period.

Drug-Eluting Balloon Market, by Product Type– 2018 and 2027



Drug-Eluting Balloon in Healthcare Market, by Product Type– 2018 and 2027
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

End User-Based Insights

In terms of end user, the Drug-Eluting Balloon market is segmented into hospitals, cath labs & cardiac centers, and ambulatory surgical centers. The hospitals segment held the largest share of the market in 2018. However, Cath labs & cardiac centers segment is estimated to register the highest CAGR of 16.5% in the market during the Forecast period.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Drug-Eluting Balloon Market: Strategic Insights

drug-eluting-balloons-market
Market Size Value inUS$ 516.65 Million in 2018
Market Size Value byUS$ 1,870.60 Million by 2027
Growth rateCAGR of 15.6% from 2019-2027
Forecast Period2019-2027
Base Year2019
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

The Drug-Eluting Balloon market players are adopting the product launch and expansion strategies to cater to changing customer demands worldwide, which also allows them to maintain their brand name globally.

Drug-Eluting Balloon Market – by Product Type

  • Coronary Drug-Eluting Balloons
  • Peripheral Drug-Eluting Balloons
  • Other Product Types

Drug-Eluting Balloon Market – by End User

  • Hospitals
  • Cath Labs & Cardiac Centers
  • Ambulatory Surgical Centers

Drug-Eluting Balloon Market – by Geography

  • North America

    • US
    • Canada
    • Mexico
  • Europe

    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)

    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of APAC
  • Middle East & Africa (MEA)

    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of MEA
  • South America and Central America (SCAM)

    • Brazil
    • Argentina
    • Rest of SCAM

Company Profiles

  • Medtronic plc
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cook Medical
  • B. Braun Melsungen AG
  • Koninklijke Philips N.V.
  • Opto Circuits Limited
  • Terumo Corporation
  • Biotronik SE & Co. KG
  • Innvolution Healthcare Pvt. Ltd
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Product Type ; End User , and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina

The List of Companies

  1. Koninklijke Philips N.V.
  2. Concept Medical Inc.
  3. Opto Circuits (India) Limited (Eurocor Tech GmbH)
  4. Terumo Corporation
  5. BIOTRONIK SE & Co. KG
  6. Innvolution Healthcare Pvt. Ltd.
  7. Medtronic Plc
  8. BD
  9. Boston Scientific Corporation
  10. Cook Medical
  11. B. Braun Melsungen AG

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Drug-Eluting Balloon Market